VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Too Old to Operate11h
Exploring taVNS as a Treatment for CIPN
The following is a summary of “Feasibility of trancutaneous auricular vagus nerve stimulation in Black and Hispanic/Latino people with peripheral neuropathy,” published in the January 2025 issue of ...
FDA approves Vertex’s acute pain treatment Journavx
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...